Emergent adds new space for biotech start-ups

Emergent Technologies (ETI) has doubled its office space, taking new digs in Austin that includes new laboratory space for the biotech companies that it helps foster. ETI specializes in creating new companies that are engaged in commercializing research pioneered at regional universities.

Thomas Harlan, president and CEO of ETI, told the Austin Business Journal that the company had just run out of room. ETI moved from 12,000 square feet into 23,000 square feet of space. ETI closed a $27 million fund in the spring of 2007 and used the money to launch three companies: Mimetic Solutions, Beacon Sciences and AeonClad Coatings.

"The biotech sector is a limitless one," Harlan told the newspaper. "We're delighted to be sitting in a region where there's abundant deal flow, in terms of the science coming from the university."

- read the report in the Austin Business Journal

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.